Last reviewed · How we verify
Placebo Inhalation Powder NDPI — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo Inhalation Powder NDPI (Placebo Inhalation Powder NDPI) — GlaxoSmithKline. Placebo has no active pharmacological mechanism and produces no therapeutic effect beyond the placebo response.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo Inhalation Powder NDPI TARGET | Placebo Inhalation Powder NDPI | GlaxoSmithKline | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo Inhalation Powder NDPI CI watch — RSS
- Placebo Inhalation Powder NDPI CI watch — Atom
- Placebo Inhalation Powder NDPI CI watch — JSON
- Placebo Inhalation Powder NDPI alone — RSS
Cite this brief
Drug Landscape (2026). Placebo Inhalation Powder NDPI — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-inhalation-powder-ndpi. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab